Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Mar 17, 2022

  • Corporate

Notice of the Settlement of Patent Infringement Litigation

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Osamu Okuda
Inquiries to: Toshiya Sasai
Head of Corporate Communications Dept.

Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo, Japan, hereafter Chugai) announced that it has entered into settlement agreement with Alexion Pharmaceuticals, Inc. (Headquarters: Massachusetts, USA, hereafter Alexion) today relating to patent litigations filed by Chugai against Alexion's anti-complement antibody product ULTOMIRIS® (ravulizumab). In accordance with this settlement agreement, Chugai together with Alexion will take steps to withdraw the following patent infringement proceedings:

<Patent Infringement Lawsuits to be withdrawn>

    1. Lawsuit filed at the United States District Court for the District of Delaware
      Dates of Complaint: November 15, 2018, and November 13, 2019 (additional) (U.S. Eastern Standard Time)
      Defendant: Alexion Pharmaceuticals, Inc.
      Patents in suit: U.S. Patent No. 9,890,377 and No. 10,472,623
    2. Lawsuit filed at the Tokyo District Court
      Date of Complaint: December 5, 2018 (Japan Standard Time)
      Defendant: Alexion Pharma Godo Kaisha (Japan Regional Headquarters)
      Patents in suit: Japanese Patent No. 4954326 and No. 641743

As a result of the settlement reached between the two companies, Chugai expects to receive a lump-sum payment of $775 million from Alexion. Other than the lump-sum payment, no other payment and no ongoing royalties will be made or received between the two companies under this settlement agreement.

The impact of this matter on the consolidated financial results for the fiscal year ending December 2022 is currently under review. We will promptly disclose any matters that should be disclosed in the future.


  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail:
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail:
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top